This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cerebral Infarction — NIHSS≥5 Acute Phase, V275뇌경색증 — NIHSS≥5 급성기

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I63 (cerebral infarction) | Special Copayment Reduction: V275 (Special Copayment Reduction for acute cerebral infarction: NIHSS≥5 with thrombolysis or thrombectomy performed within 24 hours of onset, 5% copayment for up to 30 days)
B. SynonymsIschemic stroke, acute ischemic stroke (AIS), acute cerebral infarction, cerebral infarction, cerebral thrombosis and cerebral embolism (detailed classification by cause)
C. Adult onsetIncidence rises sharply at age 55 and over; moderate to severe cerebral infarction with NIHSS≥5 is common in older patients, large vessel occlusion and cardioembolism. V275 applies on the condition that thrombolysis or thrombectomy is performed within 24 hours of onset.
1. HistorySummarizes the historic turning points in the treatment of acute cerebral infarction, from the NINDS rt-PA study (1995) to thrombectomy (SWIFT PRIME, MR CLEAN, etc., 2015).
2. CausesAortic atherosclerosis (about 25%), cardioembolism (about 25%, atrial fibrillation, etc.), small vessel disease (about 25%), other/undetermined (about 25%); TOAST classification.
3. GeneticsCADASIL (NOTCH3), sickle cell anemia, MELAS (mitochondrial variants), factor V Leiden, MTHFR; polygenic risk assessment research under way.
4. General epidemiologyAbout 12 million cases per year worldwide; about 100,000 new cases per year in Korea; mortality and disability rates continue to decline, but the absolute burden remains large.
5. PathophysiologyVessel occlusion → formation of the ischemic core and penumbra → ischemic cascade (excitotoxins, oxidative stress, inflammation) → cell necrosis.
6. SymptomsHemiplegia, unilateral sensory loss, aphasia, facial palsy, visual field defects, dizziness, gait disturbance; NIHSS≥5 indicates a moderate or greater neurological deficit.
7. SignsFocal neurological deficits by NIHSS item; signs of large vessel occlusion (LVO sign); signs of brain herniation (large hemispheric infarction).
8. ScreeningRapid integrated approach of NIHSS assessment + non-contrast CT (exclusion of hemorrhage) + CTA (confirmation of LVO) + CT/MRI perfusion imaging (assessment of the penumbra).
9. DiagnosisConfirmed with non-contrast CT + MRI (DWI); LVO confirmed with CTA; risk of hemorrhagic transformation assessed with the ASPECTS score; cause identified with the TOAST classification.
10. TreatmentIntravenous thrombolysis (IV t-PA/TNK-tPA, within 4.5 hours), mechanical thrombectomy (EVT, LVO within 24 hours), antiplatelet and anticoagulant therapy, intensive stroke care.
11. PrognosisPretreatment NIHSS, infarct size and success of reperfusion are the key determinants of prognosis; with successful thrombectomy, the rate of achieving 90-day mRS 0–2 is about 40–50%.
12. PreventionControl of hypertension, diabetes and dyslipidemia, smoking cessation, anticoagulation for atrial fibrillation, antiplatelet therapy (secondary prevention) and emergency management of TIA are key.
13. ReferencesPowers WJ et al. 2019 AHA/ASA guideline for early management of patients with acute ischemic stroke … and 9 other papers

1. History

The history of treatment of cerebral infarction (ischemic stroke) is one of the areas that has undergone the most dramatic change in modern neurology. For a long time stroke was regarded as untreatable, and patients received only rest and supportive care after admission. Even until the mid-20th century, acute stroke treatment was limited to infection prevention, blood pressure control and nutritional support.

In 1958 Claude Miller reported the effectiveness of carotid endarterectomy (CEA), beginning the surgical approach to stroke prevention. In the 1960s–1970s the introduction of CT made it possible to distinguish hemorrhagic from ischemic stroke, which became the basis for differentiating treatment strategies. Tissue-type plasminogen activator (t-PA) was first introduced for the treatment of myocardial infarction in the early 1980s, and attempts to apply it to acute cerebral infarction followed.

In 1995 the NINDS (National Institute of Neurological Disorders and Stroke) study confirmed that intravenous rt-PA given within 3 hours of symptom onset significantly improves 90-day neurological outcomes in patients with ischemic stroke (N Engl J Med, 1995). This is the most important milestone in the history of acute cerebral infarction treatment. Subsequently, the ECASS III study (2008) confirmed the effect of t-PA within 3–4.5 hours of symptom onset, extending the treatment window.

The revolution in mechanical thrombectomy (endovascular thrombectomy, EVT) came in 2015. Five randomized controlled trials published that same year — MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA and THRACE — all simultaneously reported that EVT produced markedly better neurological outcomes than standard treatment in acute ischemic stroke due to large vessel occlusion (LVO). These studies played a decisive role in establishing EVT as the standard treatment for acute LVO cerebral infarction. In 2018 the DAWN and DEFUSE 3 studies demonstrated that EVT is effective even in the late time window of 6–24 hours after last known well with appropriate imaging-based patient selection, further extending the treatment window. In Korea, reflecting this international evidence, the V275 Special Copayment Reduction was introduced to improve access to this important treatment by reducing the copayment to 5% for up to 30 days in moderate to severe acute cerebral infarction with NIHSS ≥5 in which thrombolysis or thrombectomy was performed within 24 hours of onset.


2. Causes

The TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification is used as the standard for classifying the causes of cerebral infarction, dividing them into five subtypes according to cause.

Large-artery atherosclerosis accounts for about 25% of the total; the mechanism is thrombus formation or distal embolism from atherosclerotic plaques in major vessels such as the carotid, vertebral, basilar and middle cerebral arteries. Artery-to-artery embolism is an important mechanism. Hypertension, diabetes, hyperlipidemia and smoking are the main risk factors. Cardioembolism accounts for about 25%, and atrial fibrillation is the most common cause (about 15% of all ischemic strokes). Other cardioembolic sources include valvular disease (especially mitral stenosis), myocardial infarction (especially left ventricular thrombus after anterior wall infarction), prosthetic valves, endocarditis, intracardiac tumors (myxoma) and atrial septal defect. In cardioembolism, cerebral infarcts tend to be large and to involve the cortex.

Small-vessel disease (lacunar stroke) accounts for about 25% and is characterized by small infarcts (< 15 mm) due to lipohyalinosis and microatheroma of small cerebral arteries (diameter 100–400 μm). It predominantly affects areas supplied by penetrating arteries, such as the putamen, thalamus, internal capsule, pons and cerebellum. Hypertension is the most important risk factor. Other determined causes include arterial dissection, vasculitis, thrombophilia, moyamoya disease, venous sinus thrombosis, drug-related causes (cocaine, etc.) and rare genetic diseases (CADASIL, etc.). Cryptogenic stroke accounts for about 25%, and research on early detection of atrial fibrillation in this category has recently been active.


3. Genetics

The genetics of ischemic stroke are divided into monogenic causes and polygenic predisposition.

The most important monogenic stroke syndrome is CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), caused by mutations in the NOTCH3 (19p13) gene. It is characterized by recurrent small vessel cerebral infarcts and white matter changes and has high early mortality. CARASIL (HTRA1 mutations) is autosomal recessive with a similar clinical picture. In MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes), the m.3243A>G variant of mitochondrial DNA is the most common, and recurrent stroke-like episodes and hyperlactatemia in young patients are characteristic.

In sickle cell disease, HBB gene variants produce abnormal hemoglobin S, causing vascular occlusion and cerebral infarction. It is an important cause of pediatric stroke. In thrombophilia, factor V Leiden (F5 gene), the prothrombin G20210A variant (F2) and the MTHFR C677T variant (abnormal homocysteine metabolism) are reported to raise the risk of ischemic stroke, but the overall effect size is small. GWAS of all ischemic stroke have identified several loci, including PITX2 (atrial fibrillation–related), HDAC9 (aortic atherosclerosis–related) and 9p21 (shared with coronary artery disease). Currently, genetic testing in clinical practice is performed selectively in patients suspected of having a monogenic cause.


4. General epidemiology

Ischemic stroke accounts for about 85–90% of strokes worldwide and is the most frequent type of stroke. About 12 million new ischemic stroke patients are estimated to occur worldwide each year.

Looking at epidemiology in Korea, data from the Health Insurance Review & Assessment Service (HIRA) and the national stroke registry show about 100,000–110,000 new stroke patients annually, of whom about 70–80% have ischemic stroke. The incidence of ischemic stroke in Korea is about 70–100 per 100,000 and is steadily declining, but the absolute number of patients is increasing because of population aging. By sex, incidence is slightly higher in men, and by age, incidence rises sharply at age 60 and over. A characteristic of the etiologic classification of Korean stroke patients is a relatively higher proportion of small vessel disease (lacunar infarct) than in Western countries.

Moderate to severe cerebral infarction with NIHSS ≥5 accounts for about 40–50% of all ischemic strokes, and high NIHSS scores tend to occur with large vessel occlusion (LVO) and cardioembolism. The proportion of patients eligible for thrombolysis and thrombectomy depends on appropriate hospital arrival and shortening of time to treatment; the rate of thrombectomy in Korea has increased sharply in recent years, and in the 2020s it is performed in about 20–30% of patients with LVO stroke.


5. Pathophysiology

The pathophysiology of ischemic stroke is understood as a cascade of vessel occlusion, cerebral ischemia, cellular injury and secondary brain injury.

Vessel occlusion and cerebral ischemia: when a cerebral vessel is occluded by thrombus or embolus, cerebral blood flow to that territory decreases. Normal cerebral blood flow (CBF) is about 50 mL/100g/min; when it falls below 20 mL/100g/min, neurological dysfunction begins, and below 10 mL/100g/min cell necrosis proceeds. The ischemic core is the area where blood flow has completely stopped, and irreversible cell necrosis occurs within minutes. The ischemic penumbra surrounds the core and is salvageable tissue in which blood flow is reduced but cell necrosis has not yet occurred. Because it can be rescued by reperfusion, it is the main therapeutic target of thrombolysis and thrombectomy.

Ischemic cascade: cellular ATP depletion → Na+/K+ ATPase failure → intracellular sodium and calcium influx → cellular edema. Overactivation of voltage-dependent calcium channels and NMDA receptors causes excessive intracellular calcium influx → glutamate release → excitotoxic cell death. Generation of reactive oxygen species (ROS) → membrane lipid peroxidation, DNA damage. Blood-brain barrier (BBB) disruption → vasogenic edema, risk of hemorrhagic transformation. Inflammatory response (activation of brain macrophages and microglia, neutrophil infiltration) → expansion of the infarct area. Reperfusion injury — a surge of reactive oxygen species and vascular endothelial damage — must also be considered after treatment.


6. Symptoms

The symptoms of ischemic stroke vary with the infarct location, and NIHSS≥5 indicates a moderate or greater neurological deficit.

Anterior circulation infarction: middle cerebral artery (MCA) territory infarction is the most common, presenting with contralateral hemiplegia and unilateral sensory loss, gaze deviation toward the side of the lesion, hemianopia, and aphasia when the dominant hemisphere is involved. Complete occlusion of the internal carotid artery (ICA) may be accompanied by ipsilateral monocular visual disturbance and contralateral hemibody symptoms. Anterior cerebral artery (ACA) territory infarction is characterized by leg-predominant hemiplegia and voiding dysfunction.

Posterior circulation infarction: basilar artery (BA) occlusion presents with decreased consciousness, quadriplegia and eye movement disorders and has a serious course. Vertebral artery (VA) or posterior inferior cerebellar artery (PICA) infarction is characterized by Wallenberg syndrome — dizziness, gait disturbance, ipsilateral facial sensory loss, contralateral limb sensory loss, dysphagia, hoarseness and Horner syndrome. The high neurological deficit reaching NIHSS≥5 is typical of major vessel occlusions such as MCA trunk (M1) occlusion, ICA terminus occlusion and basilar artery occlusion. These patients are candidates for thrombolysis or thrombectomy within 24 hours of onset, and the V275 Special Copayment Reduction applies.


7. Signs

Systematic assessment of neurological deficits on physical examination in acute ischemic stroke is key to treatment decisions.

The NIHSS (National Institutes of Health Stroke Scale) is a standard neurological deficit scale of 0–42 points. It is assessed with 11 items: level of consciousness (LOC), gaze, visual fields, facial palsy, motor arm, motor leg, limb ataxia, sensory, language, dysarthria and extinction/inattention. NIHSS 5–15 is classified as moderate, 16–20 as severe and 21–42 as very severe. NIHSS ≥5 is one of the criteria for applying the V275 Special Copayment Reduction.

Findings suggestive of large vessel occlusion (LVO): NIHSS ≥ 6 and the combination of gaze deviation, hemianopia, aphasia and hemiplegia strongly suggest LVO. In LVO studies, NIHSS ≥ 9, or the combination of an arm strength score ≥ 2 + NIHSS of 6 or more, has been reported to be useful for predicting LVO. Signs of cerebellar and brainstem infarction: nystagmus, dysmetria, diplopia, Horner syndrome and crossed sensory-motor deficits (ipsilateral face + contralateral body) strongly suggest posterior circulation infarction. In basilar artery occlusion, the combination of decreased consciousness + internuclear ophthalmoplegia (INO) + quadriplegia is characteristic. Blood pressure is commonly elevated in the acute phase of ischemic stroke (SBP > 140 mmHg in about 80%) and must be controlled to SBP < 185 mmHg and DBP < 110 mmHg or below before thrombolysis.


8. Screening

Rapid screening and evaluation of acute ischemic stroke (eligible for V275: NIHSS≥5 + treatment within 24 hours) is a process in which every minute and second counts.

Under the "Time is Brain" principle, minimizing the time from symptom onset to reperfusion is most important. Before hospital arrival, EMS (emergency medical services) recognize stroke early with FAST (Face-Arm-Speech-Time) or BE-FAST (Balance, Eyes, Face, Arm, Speech, Time) assessment and transport the patient to a stroke center. Target times after hospital arrival: arrival to CT 25 minutes, arrival to thrombolysis 60 minutes (door-to-needle ≤ 60 minutes), arrival to endovascular treatment 90 minutes (door-to-puncture ≤ 90 minutes).

Evaluations to be performed immediately: ① NIHSS assessment, ② non-contrast CT (exclusion of hemorrhage and large infarction), ③ CT angiography (CTA, confirmation of LVO), ④ blood tests (blood glucose, CBC, PT-INR, aPTT, platelets, renal function, serum electrolytes), ⑤ ECG (detection of atrial fibrillation). CT/MRI perfusion imaging (CT perfusion or MR perfusion) is additionally used to confirm LVO and assess treatable penumbra. AI-based automated image analysis software such as RAPID and VIZ AI is being used to speed treatment decisions. Telestroke networks enable remote specialist evaluation even at hospitals without dedicated stroke facilities.


9. Diagnosis

Acute ischemic stroke is diagnosed by integrating clinical assessment and imaging.

Non-contrast brain CT is the first test to exclude hemorrhage and identify large established infarction. Acute infarction is often not detected on initial CT, but the following findings suggest early infarction: the hyperdense MCA sign (direct visualization of thrombus), loss of the gray-white matter boundary (sulcal effacement), and loss of the insular cortex (insular ribbon sign). ASPECTS (Alberta Stroke Program Early CT Score) quantifies infarct extent on a scale of 0–10, with lower scores indicating more extensive infarction. ASPECTS < 6 suggests poor outcome after thrombectomy and risk of hemorrhagic transformation. Diffusion-weighted MRI (DWI) is the most sensitive method for diagnosing acute infarction, showing high signal even within minutes of onset. However, CT takes priority for immediate treatment decisions for thrombolysis and thrombectomy. CT angiography (CTA) assesses the location of the occluded vessel and clot burden to determine EVT indications. To evaluate the cause, echocardiography, Holter monitoring (detection of atrial fibrillation), transcranial Doppler and the like are performed within 24–48 hours.


10. Treatment

Rapid reperfusion is key to treating acute cerebral infarction with NIHSS≥5 within 24 hours of onset (eligible for V275).

Intravenous thrombolysis (IV thrombolysis): within 4.5 hours of symptom onset, alteplase (rt-PA) 0.9 mg/kg (maximum 90 mg, 10% IV over 1 minute and the remaining 90% as a continuous infusion over 60 minutes) is given. Tenecteplase (TNK-tPA) has recently been included in guidelines based on studies showing effects equivalent or superior to rt-PA (0.25 mg/kg, maximum 25 mg, single IV bolus). Absolute contraindications to thrombolysis: history of intracranial hemorrhage, intracranial surgery, trauma or stroke within 3 months, uncontrolled hypertension (SBP > 185 or DBP > 110 mmHg), active internal bleeding, platelets < 100,000, INR > 1.7, etc. Mechanical thrombectomy (EVT): in patients with large vessel occlusion (ICA, MCA M1, VA, BA), the thrombus is removed within 6 hours of onset (or within 24 hours based on imaging) using a stent retriever or direct aspiration technique. In the DAWN (6–24h) and DEFUSE 3 (6–16h) studies, the treatment window was extended with CTP/DWI-based patient selection. EVT can be performed in combination with thrombolysis (bridging therapy) or alone. Antiplatelet therapy: in patients who did not receive thrombolysis, aspirin 300 mg is given immediately (within 24 hours), then switched to a maintenance dose. In mild to moderate non-cardioembolic stroke, short-term dual antiplatelet therapy (DAPT) with clopidogrel and aspirin for 21 days prevents early recurrence (CHANCE and POINT studies). Intensive stroke care: admission to a stroke unit or neurocritical care unit for blood pressure, glucose and temperature control, aspiration prevention, cardiac monitoring and very early rehabilitation. In malignant cerebral edema, decompressive hemicraniectomy is considered as life-saving surgery.


11. Prognosis

The prognosis of moderate to severe cerebral infarction with NIHSS≥5 depends greatly on the treatment method and its speed.

With thrombolysis alone, the rate of achieving a good outcome (mRS 0–1) at 3 months is about 30–40% (based on the NINDS rt-PA study). With successful EVT (mTICI 2b/3 reperfusion), the rate of achieving 90-day mRS 0–2 is about 40–50%, significantly higher than in the untreated group (about 13–28%). Combined thrombolysis + EVT showed better outcomes than EVT alone in some studies, but this topic remains controversial. Prognostic determinants: the pretreatment NIHSS score is the strongest single prognostic factor. Other factors affecting prognosis include imaging-based infarct size (ASPECTS), time to treatment (door-to-recanalization time), success of reperfusion (mTICI grade), age and comorbidities (diabetes, etc.). In untreated patients with NIHSS≥5, 90-day mortality is about 15–25%, and neurological disability (mRS ≥ 3) occurs in about 50–70%. Early neurological deterioration occurs in about 25%, caused by hematoma expansion, reocclusion, edema and the like.


12. Prevention

Prevention of cerebral infarction is divided into primary prevention (before onset) and secondary prevention (prevention of recurrence after onset).

In primary prevention, control of vascular risk factors is most effective. Treatment of hypertension (target SBP < 130 mmHg) is the most effective single intervention in primary stroke prevention. Treatment of dyslipidemia: statin therapy reduces stroke risk by about 17–25%. Diabetes control: maintaining glucose targets reduces stroke risk. Smoking cessation and increased physical activity are important lifestyle modifications. In patients with atrial fibrillation, anticoagulation (DOAC, warfarin) is the most powerful preventive treatment, reducing stroke risk by about 64–70%. In secondary prevention, the keys are antiplatelet therapy (non-cardioembolic stroke) — aspirin 75–100 mg/day or clopidogrel 75 mg/day — intensive statin therapy (target LDL < 70 mg/dL), blood pressure control and anticoagulation for atrial fibrillation. After TIA or minor stroke, 21 days of DAPT (aspirin + clopidogrel) followed by switching to single antiplatelet therapy is recommended. In symptomatic carotid stenosis (≥ 70%), CEA or stenting is effective in preventing recurrence.


13. References

  1. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke. Stroke. 2019;50(12):e344-e418. DOI: 10.1161/STR.0000000000000211. PMID: 31662037.

  2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587. DOI: 10.1056/NEJM199512143332401. PMID: 7477192.

  3. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials (HERMES). Lancet. 2016;387(10029):1723-1731. DOI: 10.1016/S0140-6736(16)00163-X. PMID: 26898852.

  4. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct (DAWN). N Engl J Med. 2018;378(1):11-21. DOI: 10.1056/NEJMoa1706442. PMID: 29129157.

  5. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging (DEFUSE 3). N Engl J Med. 2018;378(8):708-718. DOI: 10.1056/NEJMoa1713973. PMID: 29364767.

  6. Wang Y, Meng X, Wang A, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with TIA or minor stroke (CHANCE-2). N Engl J Med. 2021;385(27):2520-2530. DOI: 10.1056/NEJMoa2111749. PMID: 34780667.

  7. Badhiwala JH, Nassiri F, Alhazzani W, et al. Endovascular thrombectomy for acute ischemic stroke: a meta-analysis. JAMA. 2015;314(17):1832-1843. DOI: 10.1001/jama.2015.13767. PMID: 26547467.

  8. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929-1935. DOI: 10.1016/S0140-6736(14)60584-5. PMID: 25106063.

  9. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10. DOI: 10.1056/NEJM200101043440101. PMID: 11136953.

  10. Hong KS, Ko SB, Lee JS, et al. Endovascular recanalization therapy in acute ischemic stroke: updated meta-analysis of randomized controlled trials. J Stroke. 2015;17(3):268-281. DOI: 10.5853/jos.2015.17.3.268. PMID: 26437992.